Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Syngene International Limited

NSE: SYNGENEHealthcare Research, Analytics & Technology

Share price

₹346.00

-3.97% close of 8 Oct 2026

Market cap ₹13,944 CrP/E 47.3

Business score

How strong the business is, in one number. The parts behind it are in Pro.

59

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹13,944 Cr

P/E ratio

47.3

P/B ratio

2.9

ROCE

10.0%

ROE

7.8%

Dividend yield

0.4%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹663.8552-week low ₹346.00

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales fell 3.4% over the past year. Meanwhile what it keeps of every 100 rupees of sales slipped from 30.2% to 21.6% over the last four years.

Whether it grew faster than its sector

It grew 14.7% a year against a sector median of 13.1% — 1.6 percentage points faster.

Room to re-rate, or risk of de-rating

At 47.3× earnings it costs 2.0× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 21.9×, across 4 companies. It is against its own five-year median of 56.3×, the 8th percentile of its own range.

Whether growth justifies the valuation

Its earnings are falling, so growth cannot justify the price.

Profit growthPrice per ₹1 profitPer 1% growth
Syngene International Limited — this one-8%/yr47.3×—
Indegene Limited16%/yr33.8×₹2.1
Suven Life Sciences Limited———
Vimta Labs Limited19%/yr31.1×₹1.6
Fabtech Technologies Limited19%/yr12.7×₹0.67
Bilcare Limited32%/yr11.1×₹0.35

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Healthcare Research, Analytics & Technology), it ranks 5 of 7 on returns, 3 of 6 on growth, 2 of 7 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 10.0% on capital, ahead of 29% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹4530 crore of cash from the business, spent ₹2622 crore on plant and equipment, and returned ₹1281 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 9 years, about 192 arrived as cash — well above the profit, more than depreciation and interest account for, so do not count on it repeating. Its cash comes back faster than it used to: it went from being paid 43 days before it paid its own suppliers to paid 68 days before it paid its own suppliers.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

9 of 9 checks clear · 100%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Syngene slipped to a small loss in the June quarter as sales fell about 16% from a year earlier, with the shortfall on one large customer's product still working through.

Announced 29 Jul 2026 · Consolidated

Revenue

₹736 Cr

Revenue vs last year

-15.8%

Revenue vs last quarter

-29.0%

Net profit

-₹9 Cr

Profit vs last year

-110.3%

Profit vs last quarter

-106.1%

Net margin

-1.2%

EPS

₹-0.22

Earnings call transcript · 30 Jul 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹13,944 Cr
Prev close
₹346.00
52w High
₹679
52w Low
₹345
Enterprise value
₹13,113 Cr
Beta
0.8
Price CAGR 1y
-43.0%
Price CAGR 3y
-23.0%
Price CAGR 5y
-10.0%
Price CAGR 10y
4.0%

Ratios

Return on assets
4.5%
PEG ratio
-5.9
P/E ratio
47.3
P/B ratio
2.9
EV / EBITDA
16.3
Industry P/E
31.2
ROCE
10.0%
ROCE 5y average
13.2%
ROE
7.8%
Debt / Equity
0.1
Interest coverage
9.4
Dividend yield
0.4%
ROE 3y average
10.0%
ROE last year
8.0%

Annual P&L

Annual revenue
₹3,739 Cr
Annual profit
₹317 Cr
Operating margin
25.0%
Net profit margin
8.5%
EBITDA margin
24.6%
Sales growth 3y
5.4%
Sales growth 5y
11.4%
Profit growth 3y
-8.0%
Profit growth 5y
0.0%
EPS
₹7.9
Sales growth TTM
-3.0%
Profit growth TTM
-42.0%
Dividend payout
16.0%

Quarter P&L

Sales latest quarter
₹736 Cr
Profit latest quarter
-₹9 Cr
YoY quarterly sales growth
-15.8%
YoY quarterly profit growth
-110.4%
OPM latest quarter
12.3%

Balance Sheet

Book Value
₹120
Face Value
₹10.0
Total debt
₹458 Cr
Total cash
₹833 Cr
Borrowings
₹458 Cr
Reserves / Equity
11.0

Cash Flow

Operating cash flow
₹915 Cr
Free cash flow
₹547 Cr
FCF yield
3.6%
Net cash flow
-₹138 Cr

Shareholding

Promoter holding
52.6%
FII holding
11.8%
DII holding
28.0%
Public holding
7.2%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Indegene589.9034.114,2120.37116.2-0.21,063.139.718.8
Syngene Intl.348.0047.414,0480.36-9.0-94.9736.0-15.810.0
Suven Life Scie.290.758,2160.00-127.6-147.73.690.9-79.5
Vimta Labs553.1530.62,4730.3521.011.4109.111.825.2
Fabtech Tech.140.0012.86220.444.2154.875.010.313.6
Bilcare93.1111.02190.0015.0473.1225.921.27.1
Novelix Pharma.67.0552.71910.001.2972.736.965.210.9
Median140.0033.16220.001.2117.475.030.510.9

Competes with: Bilcare Limited, Fabtech Technologies Limited, Indegene Limited, Suven Life Sciences Limited, Take Solutions Limited, Vimta Labs Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales8089108549177908919441,0188759119171,037736
Expenses596656622600620646660674668711708733645
Material Cost228240228221223178
Change in Inventories6.90-22118.509.80-4.80
Purchases of Stock-in-Trade000000
Employee Cost253262275267301259
Other Expenses186189198211199213
Operating Profit21225423231717024528434420620020930391
OPM %26282735222730342422232912
Other Income24142616501718191815-551612
Exceptional items (within Other Income)000-71-6-14
Interest1113111312131216121312129.60
Depreciation102105108111107111109106111117114112112
Profit before tax1231511382091011371812411018528196-19
Tax %2423199.762523272414214725-53
Net Profit9311711218976106131183876715148-9
EPS in Rs2.322.902.774.691.882.643.264.552.151.670.373.67-0.22
Diluted EPS in Rs4.562.151.670.373.67-0.22

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,4231,8262,0122,1842,6043,1933,4893,6423,7393,600
Expenses9491,2891,3941,5071,8612,2512,4722,5982,8172,797
Material Cost925911
Change in Inventories177.40
Purchases of Stock-in-Trade00
Employee Cost9841,105
Other Expenses674797
Operating Profit4745376186787439421,0171,045921803
OPM %33293131293029292522
Other Income537515394756377101-9-12
Exceptional items (within Other Income)32-77
Interest23323528244547534947
Depreciation131164219274310366426433453454
Profit before tax372415517469484594621660411290
Tax %182020141822182523
Net Profit305332412405396464510496317221
EPS in Rs7.648.2910109.881213127.865.49
Diluted EPS in Rs127.87
Dividend Payout %73001011101016

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
11%
3 years
5%
TTM
-3%

Compounded profit growth

10 years
—
5 years
0%
3 years
-8%
TTM
-42%

Stock price CAGR

10 years
4%
5 years
-10%
3 years
-23%
1 year
-43%

Return on equity

10 years
—
5 years
11%
3 years
10%
Last year
8%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital200200400400401401402403403
Reserves1,5201,7681,7762,4212,8973,2173,8564,3244,436
Borrowings7878137738931,022815555578458
Other Liabilities6819221,2141,1691,2451,3981,3391,4911,757
Total Liabilities3,1893,7044,1634,8835,5645,8316,1526,7967,055
Fixed Assets1,0301,3772,0202,2012,3932,6672,8502,8023,000
CWIP1552742342373461778381,2661,046
Investments1587167767021,034918548647741
Other Assets1,8461,3371,1331,7431,7902,0691,9162,0812,268
Total Assets3,1893,7044,1634,8835,5645,8316,1526,7967,055

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity4466306777015818241,0421,168915
Cash from Investing Activity-349-646-424-629-611-653-494-744-839
Cash from Financing Activity-79-72-22658-31-342-551-142-215
Net Cash Flow18-8828130-62-172-4281-138
Free Cash Flow824734255105305553398547

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days686872797161465350
Inventory Days8230184187141946056
Days Payable195154156167113109100136138
Cash Conversion Cycle-44-56-66-47459240-23-32
Working Capital Days-48-103-172-66-43-14-27-51-68
ROCE %1717141315151310

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters555555555553535353535353
FIIs242121212121191716151412
DIIs121516171720222425262628
Public9.479.078.187.446.746.795.996.456.086.226.697.15
Others0.480.320.310.430.340.290.290.310.300.290.290.43
No. of Shareholders1,25,9921,21,8801,15,8501,20,0181,07,3381,28,8061,25,0901,42,3101,36,0611,31,7501,35,6051,42,277

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -45.8% (₹638.60 → ₹346.00)Brick size ₹10.29 (fixed)Bricks 63
₹400₹500₹600₹346Nov '25Jan '26Mar '26May '26Aug '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹346.00 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-831inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

55,87,268inr

2026-03-31

News

News and filings about Syngene International Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • biology reagents and consumables
  • catalog chemicals
  • chemicals, reagents and lab consumables
  • key starting materials (KSMs)
  • lab electronics and capital equipment

Depends on the price of

  • fuel
  • water

Sells to

  • Amgen · integrated discovery, development & manufacturing (CRDMO) services / dedicated R&D center
  • Baxter · integrated discovery, development & manufacturing (CRDMO) services / dedicated R&D center
  • Bristol Myers Squibb · integrated discovery, development & manufacturing (CRDMO) services / dedicated R&D center
  • GSK · integrated discovery, development & manufacturing (CRDMO) services / dedicated R&D center
  • Merck KGaA · integrated discovery, development & manufacturing (CRDMO) services / dedicated R&D center
  • Zoetis · integrated discovery, development & manufacturing (CRDMO) services / dedicated R&D center

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Healthcare Research, Analytics & Technology
Classification
Healthcare › Healthcare Research, Analytics & Technology
ISIN
INE398R01022

Plants

  • Baltimore-Bayview Manufacturing Site · Baltimore, Maryland, United States
  • Biocon Park SEZ main campus (Bommasandra)
  • Hyderabad discovery research hub · Hyderabad, Telangana
  • Mangaluru API / small-molecule facility
  • Unit 3 multi-modal biologics manufacturing facility · Bengaluru, Karnataka

News impact

Big market events that reach Syngene International Limited, and how the effect spreads.

Who it hits first

  • Pentagon Biosecure blacklist on WuXi AppTec — US biotech contracts pivot to India CRAMS; multi-year tailwind

Who may gain

  • SYNGENE
  • DIVISLAB
  • LAURUSLABS
  • GLENMARK

Along the supply chain

Downstream

US biotech delivery timelines stabilize; cost slightly higher than China but compliance certain

Upstream

Higher API + intermediate procurement from India over China

Where demand moves

Business

US biotech R&D contracts reroute from WuXi to Indian CDMOs; Asian capacity rationalisation

Capital

Long-only allocation into Indian CRAMS theme; ETF flows benefit

How it spreads across sectors

CRAMS

primary beneficiary

Healthcare

CRAMS sub-sector elevation

Pharma

structural positive

When it plays out

Immediate

Sector pop 2-4%

Medium term

Multi-year capacity expansion + multiple expansion

Short term

Contract pipeline visibility improves

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

25 Jun 2026unspecified₹1.25
27 Jun 2025unspecified₹1.25
28 Jun 2024unspecified₹1.25
30 Jun 2023unspecified₹0.5
30 Jun 2023special₹0.75
30 Jun 2022unspecified₹0.5
30 Jun 2022special₹0.5
16 Jul 2019unspecified₹0.5

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
30 Apr 2026MICROCURVES TRADING PRIVATE LIMITEDBUY27,66,287₹481.90
30 Apr 2026MICROCURVES TRADING PRIVATE LIMITEDSELL27,66,287₹482.02
30 Apr 2026NK SECURITIES RESEARCH PRIVATE LIMITEDBUY21,60,599₹486.40
30 Apr 2026NK SECURITIES RESEARCH PRIVATE LIMITEDSELL21,60,599₹486.62

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.